The landscape for weight-loss and diabetes treatment shifted dramatically over the weekend as at least six Indian pharmaceutical companies introduced generic versions of Novo Nordisk A/S’ (NYSE:NVO) blockbusters Ozempic and Wegovy.

Following the expiration of the Indian patent for semaglutide last week, these manufacturers are offering treatments at globally unmatched prices, effectively reducing costs by approximately 70%.

Indian Pharma Targets $100 Billion Global Obesity Market

Citing industry experts, Reuters report on Monday anticipates that more than 40 domestic firms will eventually release over 50 affordable variants of the drug.

Major players are looking beyond local borders, eyeing future launches in Canada, Brazil, Latin America, and Turkey to capture a portion of the global obesity market, which is forecasted to reach $100 billion by the end of the decade.

Major Generic Launches And Pricing

Sun Pharmaceutical Industries, India's largest drugmaker, debuted its injectable semaglutide under the brand Noveltreat for weight management and Sematrinity for Type 2 diabetes.

Reuters ...